Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two antiviral drugs: simeprevir and tenofovir disoproxil fumarate. Simeprevir (TMC435) is an oral hepatitis C virus NS3/4A protease inhibitor developed for the treatment of chronic hepatitis C infection. Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor used primarily in the treatment of HIV infection and chronic hepatitis B. Tenofovir DF works by inhibiting viral reverse transcriptase, leading to chain termination during viral DNA synthesis, while simeprevir inhibits the HCV NS3/4A protease, preventing viral replication. This combination may be considered in patients with co-infection or as part of broader antiviral regimens.
- Brand names
- Viread (for tenofovir disoproxil fumarate)
- Other names
- simeprevir (for TMC435)TDF (abbreviation for tenofovir disoproxil fumarate)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on simeprevir + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + tenofovir disoproxil fumarate.